NHI.no
Annonse
Informasjon

Polycytemia vera

Polycytemi innebærer økning av antall røde blodlegemer i blodet, vanligvis på grunn av annen sykdom. Ved polycytemia vera foreligger en kreftsykdom som er lite aggressiv.

Polycytemia vera opptrer oftest hos middelaldrende eller eldre mennesker.

Sist oppdatert:

10. mars 2022

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Polycytemia vera . Referanselisten for dette dokumentet vises nedenfor

  1. Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av maligne blodsykdommer. Myeloproliferative neoplasier. 2012. Sist faglig oppdatert 23. des 2021. www.helsedirektoratet.no
  2. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020 Dec;95(12):1599-1613. PMID: 32974939.
  3. Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017 Feb 9;129(6):667-679. PMID: 28028029.
  4. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.Blood 2016; 127(20): 2391-405. Blood
  5. Tefferi A, Guglielmelli P, Lasho TL et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020 Apr;189(2):291-302. PMID: 31945802.
  6. Stein BL, Oh ST, Berenzon D, et al. Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. J Clin Oncol 2015 ;33(33): 3953-60. DOI: 10.1038/s41375-018-0207-9 DOI
  7. McMullin MF, Wilkins BS, Harrison CN. Management of polycythaemia vera: a critical review of current data. Br J Haematol 2016; 172(3): 337-49. PubMed
  8. Harrison CN, Robinson SE. Myeloproliferative disorders in pregnancy. Hematol Oncol Clin North Am 2011; 25(2): 261-75. PubMed
  9. Griesshammer M, Kiladjian JJ, Besses C. Thromboembolic events in polycythemia vera. Ann Hematol. 2019;98(5):1071-1082. PubMed
  10. Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, et al. Ropeginterferon alfa-2b, a novel IFNa-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015; 126(15): 1762-1769. PubMed
  11. Gowin K, Thapaliya P, Samuelson J, et al. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial. Leuk Res. 2017; 54: 73-77. PubMed
  12. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015; 372(5): 426-35. PubMed
  13. Passamonti F, Griesshammer M, Palandri F, et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol 2017; 18: 88-99. PubMed
  14. Ahlstrand E, Andersen CL, Andreasson B et al. Nordic care program for patients with Essential Thrombocythemia, Polycythemia Vera. 4th version March 2017. Stockholm: Nordic MPD Study Group; 2017. and Primary Myelofibrosis legehandboka.no
  15. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29(6): 761-70. PubMed
  16. Szuber N, Vallapureddy RR, Penna D, et al. Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. Am J Hematol. 2018; 93: 1474–1484.
  17. Busque L, Porwit A, Day R, et al. Laboratory Investigation of Myeloproliferative Neoplasms. AJCP Am J Clin Pathol 2016; 146: 408-422. PubMed
  18. Marchioli R, Finazzi G, Specchia G, et al; CYTOPV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013; 368(1): 22-33. PubMed
Annonse
Annonse